1. Pure Bioscience (PURE)
Company Profile: Pure Bioscience develops bioscience products, including antimicrobials.
Altman Z-score: 69.8Closing Price: $2.05 (Sept. 15) Financial Metrics: Pure Bioscience has a price-to-book ratio of 11.9, which suggests the stock may be overvalued based on book value. Pure's quick ratio, which measures the ability to meet short-term obligations with its most liquid assets, is 4.9, indicating the company should be able to meet its current liabilities. Analyst Consensus: Only one firm follows Pure Bioscience, recommending that investors buy shares of the bioscience products maker -- Written by Robert Holmes in Boston.
>To contact the writer of this article, click here: Robert Holmes. >To follow Robert Holmes on Twitter, go to http://twitter.com/RobTheStreet. >To submit a news tip, send an email to: firstname.lastname@example.org.